These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33271289)

  • 1. Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Powles T;
    Ann Oncol; 2021 Mar; 32(3):422-423. PubMed ID: 33271289
    [No Abstract]   [Full Text] [Related]  

  • 2. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
    Motzer RJ; Powles T; Burotto M; Escudier B; Bourlon MT; Shah AY; Suárez C; Hamzaj A; Porta C; Hocking CM; Kessler ER; Gurney H; Tomita Y; Bedke J; Zhang J; Simsek B; Scheffold C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Jul; 23(7):888-898. PubMed ID: 35688173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
    Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.
    Wiecek W; Karcher H
    PLoS One; 2016; 11(6):e0155389. PubMed ID: 27271250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nivolumab/cabozantinib combination and the future of doublets in advanced renal cell cancer treatment.
    Lilly E; Sarkis J
    J Oncol Pharm Pract; 2021 Sep; 27(6):1553-1554. PubMed ID: 34162248
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.
    Tachibana H; Ishiyama Y; Yoshino M; Yamashita K; Toki D; Kondo T
    In Vivo; 2021; 35(3):1743-1747. PubMed ID: 33910858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma].
    Naoun N; Vano YA
    Bull Cancer; 2021 Nov; 108(11):991-993. PubMed ID: 34538614
    [No Abstract]   [Full Text] [Related]  

  • 9. CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma.
    Barthélémy P; Dutailly P; Qvick B; Perrot V; Verzoni E
    Future Oncol; 2024 Apr; 20(13):811-819. PubMed ID: 37403652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States.
    Liao W; Lei W; Feng M; Yang Y; Wu Q; Zhou K; Bai L; Wen F; Li Q
    Adv Ther; 2021 Dec; 38(12):5662-5670. PubMed ID: 34664194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison.
    Porta C; Szczylik C; Casciano R; Fu S; Amzal B; Lister J; Karcher H; Meng J; Neumann M; Dinet J
    Crit Rev Oncol Hematol; 2019 Jul; 139():143-148. PubMed ID: 30401604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
    Cella D; Motzer RJ; Suarez C; Blum SI; Ejzykowicz F; Hamilton M; Wallace JF; Simsek B; Zhang J; Ivanescu C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Feb; 23(2):292-303. PubMed ID: 35032437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
    Markham A
    Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Phase II Trial of Cabozantinib Plus Nivolumab in Patients with Non-clear-cell Renal Cell Carcinoma and Genomic Correlates.
    Xu Y; Huang Y; Zhang J
    Eur Urol; 2022 Sep; 82(3):331-332. PubMed ID: 35599185
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
    Lee CH; Voss MH; Carlo MI; Chen YB; Zucker M; Knezevic A; Lefkowitz RA; Shapnik N; Dadoun C; Reznik E; Shah NJ; Owens CN; McHugh DJ; Aggen DH; Laccetti AL; Kotecha R; Feldman DR; Motzer RJ
    J Clin Oncol; 2022 Jul; 40(21):2333-2341. PubMed ID: 35298296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
    Santoni M; Aurilio G; Massari F; Grande E; Matrana MR; Rizzo M; De Giorgi U; Incorvaia L; Martignetti A; Molina-Cerrillo J; Zabalza IO; Mollica V; Rizzo A; Battelli N; Porta C
    Clin Genitourin Cancer; 2022 Jun; 20(3):285-295. PubMed ID: 35305916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib for the treatment of renal cell carcinoma.
    Escudier B; Lougheed JC; Albiges L
    Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma.
    Liu R; Qiu K; Wu J; Jiang Y; Wu P; Pang J
    Immunotherapy; 2022 Aug; 14(11):859-869. PubMed ID: 35754404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
    Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
    Swallow E; Messali A; Ghate S; McDonald E; Duchesneau E; Perez JR
    J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.